Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 3/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | GHSR | Q92847 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.36 |
| ▸ | ITGAV | P06756 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL482592 | 0.93 | CRBN (0.55) | CRBNPTPN1PTPN6CYP3A4GHSR | |
| SCHEMBL482272 | 0.90 | CRBN (0.49) | CRBNPTPN1PTPN6PTPN2CYP3A4 | |
| SCHEMBL482815 | 0.86 | CRBN (0.56) | CRBNCYP3A4MAPK14 | |
| SCHEMBL896537 | 0.86 | CRBN (0.59) | CRBNCYP3A4MAPK14 | |
| SCHEMBL482628 | 0.85 | CRBN (0.55) | CRBNCYP3A4GHSRMAPK14 | |
| SCHEMBL482771 | 0.85 | CRBN (0.58) | CRBNCYP3A4MAPK14 | |
| SCHEMBL896183 | 0.84 | CRBN (0.56) | CRBNCYP3A4MAPK14 | |
| SCHEMBL482559 | 0.84 | CRBN (0.50) | CRBNCYP3A4MAPK14 | |
| SCHEMBL1530949 | 0.83 | CRBN (0.56) | CRBNCYP3A4MAPK14 | |
| SCHEMBL483220 | 0.83 | CRBN (0.54) | CRBNCYP3A4MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120082646-A1 | Antiviral Compounds And Uses Thereof | ABBOTT LABORATORIES (US) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120082646-A1 | Antiviral Compounds And Uses Thereof | MAVS, ZC3HAV1, EIF2AK2 | CRBN 2389/4885PTPN1 1614/4885PTPN6 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.